Targeted proteomics for validation of biomarkers in clinical samples Export

@article{citeulike:3832300, abstract = {The rapid rise and application of proteomic technologies has resulted in an exponential increase in the number of proteins that have been discovered and presented as potential' biomarkers for specific diseases. Unfortunately, the number of biomarkers approved for use by the Food and Drug Administration has not risen in likewise manner. While there are a number of reasons for this discrepancy, this glut of potential' biomarkers also indicates the need for validation methods to confirm or refute their utility in clinical diagnostics. For this reason, the emphasis on developing methods to target and measure the absolute quantity of specific proteins and peptides in complex proteomic samples has grown. 10.1093/bfgp/eln050}, author = {Ye, Xiaoying and Blonder, Josip and Veenstra, Timothy D.}, citeulike-article-id = {3832300}, citeulike-linkout-0 = {http://dx.doi.org/10.1093/bfgp/eln050}, citeulike-linkout-1 = {http://bfgp.oxfordjournals.org/content/eln050/.abstract}, citeulike-linkout-2 = {http://bfgp.oxfordjournals.org/content/eln050/.full.pdf}, citeulike-linkout-3 = {http://view.ncbi.nlm.nih.gov/pubmed/19109305}, citeulike-linkout-4 = {http://www.hubmed.org/display.cgi?uids=19109305}, day = {1}, doi = {10.1093/bfgp/eln050}, issn = {1477-4062}, journal = {Brief Funct Genomic Proteomic}, keywords = {biomarkers, ffpe, proteomics, review}, month = {March}, number = {2}, pages = {126--135}, posted-at = {2009-11-09 10:33:29}, priority = {1}, title = {Targeted proteomics for validation of biomarkers in clinical samples}, url = {http://dx.doi.org/10.1093/bfgp/eln050}, volume = {8}, year = {2009} }

TY - JOUR ID - citeulike:3832300 L3 - citeulike-article-id:3832300 N2 - The rapid rise and application of proteomic technologies has resulted in an exponential increase in the number of proteins that have been discovered and presented as potential' biomarkers for specific diseases. Unfortunately, the number of biomarkers approved for use by the Food and Drug Administration has not risen in likewise manner. While there are a number of reasons for this discrepancy, this glut of potential' biomarkers also indicates the need for validation methods to confirm or refute their utility in clinical diagnostics. For this reason, the emphasis on developing methods to target and measure the absolute quantity of specific proteins and peptides in complex proteomic samples has grown. 10.1093/bfgp/eln050 IS - 2 JF - Brief Funct Genomic Proteomic SN - 1477-4062 EP - 135 TI - Targeted proteomics for validation of biomarkers in clinical samples VL - 8 SP - 126 KW - biomarkers KW - ffpe KW - proteomics KW - review AU - Ye, Xiaoying AU - Blonder, Josip AU - Veenstra, Timothy PY - 2009/03/01/ UR - http://dx.doi.org/10.1093/bfgp/eln050 ER -